Advertisement

Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: results from the open-label, randomized phase III CanStem303C study

Published:November 10, 2022DOI:https://doi.org/10.1016/j.clcc.2022.11.002

      ABSTRACT

      Purpose

      Napabucasin is an investigational, orally administered reactive oxygen species generator bioactivated by intracellular antioxidant NAD(P)H:quinone oxidoreductase 1 that has been evaluated in various solid tumors, including metastatic colorectal cancer (mCRC). Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is hypothesized to predict response in napabucasin-treated patients with mCRC.

      Patient and Methods

      In the multi-center, open-label, phase III CanStem303C (NCT02753127) study, adults with histologically confirmed mCRC that progressed on first-line fluoropyrimidine plus oxaliplatin ± bevacizumab were randomized to twice-daily napabucasin plus FOLFIRI (napabucasin) or FOLFIRI alone (control). The primary endpoint was overall survival (OS) in the general study population and in patients with pSTAT3-positive tumors (biomarker-positive).

      Results

      In the general study population (napabucasin, n=624; control, n=629), median OS was 14.3 months for napabucasin and 13.8 months for control (hazard ratio [HR], 0.976, one-sided p=0.74). Overall, 44% of patients were biomarker-positive (napabucasin, n=275; control, n=272). In the biomarker-positive population, median OS was 13.2 months for napabucasin and 12.1 months for control (HR, 0.969; one-sided p>0.99). In the control arm, median OS was shorter for biomarker-positive vs. biomarker negative patients (12.1 vs. 18.5 months; HR, 1.518; nominal two-sided p=0.0002). The most common treatment-emergent adverse events (TEAEs) were diarrhea (napabucasin, 84.6%; control, 53.9%), nausea (60.5%, 50.5%), vomiting (41.2%, 29.3%), and abdominal pain (41.0%, 25.2%). Grade ≥3 TEAEs occurred in 73.8% of napabucasin-treated and 66.7% of control-treated patients, most commonly diarrhea (21.2%, 7.0%), neutrophil count decreased (13.7%, 19.2%), and neutropenia (13.3%, 15.2%). Safety was similar in biomarker-positive patients.

      Conclusion

      In patients with previously treated mCRC, adding napabucasin to FOLFIRI did not improve OS. Results from the control arm indicate that pSTAT3 is an adverse prognostic factor in mCRC.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Sung H
        • Ferlay J
        • Siegel RL
        • Laversanne M
        • Soerjomataram I
        • Jemal A
        • Bray F.
        Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2021; 71: 209-249
      1. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, Version 2.2021.
        Available at: www.NCCN.org. 2022; (Accessed: January 20)
      2. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer, Version 1.2021.
        Available at: www.NCCN.org. 2022; (Accessed: January 20)
        • Saunders M
        • Iveson T.
        Management of advanced colorectal cancer: state of the art.
        Br J Cancer. 2006; 95: 131-138
        • Kuipers EJ
        • Grady WM
        • Lieberman D
        • Seufferlein T
        • Sung JJ
        • Boelens PG
        • van de Velde CJ
        • Watanabe T.
        Colorectal cancer.
        Nat Rev Dis Primers. 2015; 1: 15065
        • National Cancer Institute
        Surveillance, Epidemiology, and End Results Program.
        Cancer stat facts: colorectal cancer. 2022; (Available at:) (Accessed: January 20)
        • Hess LM
        • Cui ZL
        • Mytelka DS
        • Han Y
        • Goodloe R
        • Schelman W.
        Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA.
        Int J Colorectal Dis. 2019; 34: 581-588
        • Cremolini C
        • Antoniotti C
        • Pietrantonio F
        • Berenato R
        • Tampellini M
        • Baratelli C
        • et al.
        Surrogate endpoints in second-line trials of targeted agents in metastatic colorectal cancer: a literature-based systematic review and meta-analysis.
        Cancer Res Treat. 2017; 49: 834-845
        • Arnold D
        • Stein A.
        New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy.
        Drugs. 2013; 73: 883-891
        • Van Cutsem E
        • Cervantes A
        • Adam R
        • Sobrero A
        • Van Krieken JH
        • Aderka D
        • et al.
        ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
        Ann Oncol. 2016; 27: 1386-1422
        • Hirata A
        • Hatano Y
        • Niwa M
        • Hara A
        • Tomita H.
        Heterogeneity in colorectal cancer stem cells.
        Cancer Prev Res (Phila). 2019; 12: 413-420
        • Rich JN.
        Cancer stem cells: understanding tumor hierarchy and heterogeneity.
        Medicine (Baltimore). 2016; 95 (1 Suppl): S2-S7
        • Zeuner A
        • Todaro M
        • Stassi G
        • De Maria R.
        Colorectal cancer stem cells: from the crypt to the clinic.
        Cell Stem Cell. 2014; 15: 692-705
        • Kong H
        • Chandel NS.
        Regulation of redox balance in cancer and T cells.
        J Biol Chem. 2018; 293: 7499-7507
        • Gorrini C
        • Harris IS
        • Mak TW.
        Modulation of oxidative stress as an anticancer strategy.
        Nat Rev Drug Discov. 2013; 12: 931-947
        • Shah MA
        • Rogoff HA.
        Implications of reactive oxygen species on cancer formation and its treatment.
        Semin Oncol. 2021; 48: 238-245
        • Madajewski B
        • Boatman MA
        • Chakrabarti G
        • Boothman DA
        • Bey EA.
        Depleting tumor-NQO1 potentiates anoikis and inhibits growth of NSCLC.
        Mol Cancer Res. 2016; 14: 14-25
        • Cui X
        • Jin T
        • Wang X
        • Jin G
        • Li Z
        • Lin L
        NAD(P)H:quinone oxidoreductase-1 overexpression predicts poor prognosis in small cell lung cancer.
        Oncol Rep. 2014; 32: 2589-2595
        • Ji L
        • Wei Y
        • Jiang T
        • Wang S.
        Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival.
        Int J Clin Exp Pathol. 2014; 7: 1124-1131
        • Buranrat B
        • Chau-in S
        • Prawan A
        • Puapairoj A
        • Zeekpudsa P
        • Kukongviriyapan V.
        NQO1 expression correlates with cholangiocarcinoma prognosis.
        Asian Pac J Cancer Prev. 2012; 13 (Suppl): 131-136
        • Chang AY
        • Hsu E
        • Patel J
        • Li Y
        • Zhang M
        • Iguchi H
        • Rogoff HA.
        Evaluation of tumor cell-tumor microenvironment component interactions as potential predictors of patient response to napabucasin.
        Mol Cancer Res. 2019; 17: 1429-1434
        • Froeling FEM
        • Swamynathan MM
        • Deschênes A
        • Chio IIC
        • Brosnan E
        • Yao MA
        • et al.
        Bioactivation of napabucasin triggers reactive oxygen species-mediated cancer cell death.
        Clin Cancer Res. 2019; 25: 7162-7174
        • Yu H
        • Pardoll D
        • Jove R.
        STATs in cancer inflammation and immunity: a leading role for STAT3.
        Nat Rev Cancer. 2009; 9: 798-809
        • Jarnicki A
        • Putoczki T
        • Ernst M.
        Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?.
        Cell Div. 2010; 5: 14
        • Morikawa T
        • Baba Y
        • Yamauchi M
        • Kuchiba A
        • Nosho K
        • Shima K
        • et al.
        STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers.
        Clin Cancer Res. 2011; 17: 1452-1462
        • Tsareva SA
        • Moriggl R
        • Corvinus FM
        • Wiederanders B
        • Schütz A
        • Kovacic B
        • Friedrich K.
        Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction.
        Neoplasia. 2007; 9: 279-291
        • Kusaba T
        • Nakayama T
        • Yamazumi K
        • Yakata Y
        • Yoshizaki A
        • Inoue K
        • et al.
        Activation of STAT3 is a marker of poor prognosis in human colorectal cancer.
        Oncol Rep. 2006; 15: 1445-1451
        • Corvinus FM
        • Orth C
        • Moriggl R
        • Tsareva SA
        • Wagner S
        • Pfitzner EB
        • et al.
        Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth.
        Neoplasia. 2005; 7: 545-555
        • Kusaba T
        • Nakayama T
        • Yamazumi K
        • Yakata Y
        • Yoshizaki A
        • Nagayasu T
        • Sekine I.
        Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors.
        J Clin Pathol. 2005; 58: 833-838
        • Jonker DJ
        • Nott L
        • Yoshino T
        • Gill S
        • Shapiro J
        • Ohtsu A
        • et al.
        Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.
        Lancet Gastroenterol Hepatol. 2018; 3: 263-270
        • Bendell JC
        • O'Neil BH
        • Starodub A
        • Jonker DJ
        • Halfdanarson TR
        • Edenfield WJ
        • et al.
        Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).
        J Clin Oncol. 2017; 35 (_suppl): 593
        • Eisenhauer EA
        • Therasse P
        • Bogaerts J
        • Schwartz LH
        • Sargent D
        • Ford R
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Dmitrienko A
        • Tamhane AC.
        Mixtures of multiple testing procedures for gatekeeping applications in clinical trials.
        Stat Med. 2011; 30: 1473-1488
        • Dmitrienko A
        • Tamhane AC.
        General theory of mixture procedures for gatekeeping.
        Biom J. 2013; 55: 402-419
        • Kordzakhia G
        • Brechenmacher T
        • Ishida E
        • Dmitrienko A
        • Zheng WW
        • Li DF.
        An enhanced mixture method for constructing gatekeeping procedures in clinical trials.
        J Biopharm Stat. 2018; 28: 113-128
        • Van Cutsem E
        • Tabernero J
        • Lakomy R
        • Prenen H
        • Prausová J
        • Macarulla T
        • Ruff P
        • van Hazel GA
        • Moiseyenko V
        • Ferry D
        • McKendrick J
        • Polikoff J
        • Tellier A
        • Castan R
        • Allegra C
        Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
        J Clin Oncol. 2012; 30: 3499-3506
        • Peeters M
        • Price TJ
        • Cervantes A
        • Sobrero AF
        • Ducreux M
        • Hotko Y
        • André T
        • Chan E
        • Lordick F
        • Punt CJ
        • Strickland AH
        • Wilson G
        • Ciuleanu TE
        • Roman L
        • Van Cutsem E
        • Tzekova V
        • Collins S
        • Oliner KS
        • Rong A
        • Gansert J.
        Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
        J Clin Oncol. 2010; 28: 4706-4713
        • Tabernero J
        • Yoshino T
        • Cohn AL
        • Obermannova R
        • Bodoky G
        • Garcia-Carbonero R
        • Ciuleanu TE
        • Portnoy DC
        • Van Cutsem E
        • Grothey A
        • Prausová J
        • Garcia-Alfonso P
        • Yamazaki K
        • Clingan PR
        • Lonardi S
        • Kim TW
        • Simms L
        • Chang SC
        Nasroulah F; RAISE Study Investigators. Ramucirumab versus placebo in combination with second- line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
        Lancet Oncol. 2015; 16: 499-508
        • Xu RH
        • Muro K
        • Morita S
        • Iwasa S
        • Han SW
        • Wang W
        • Kotaka M
        • Nakamura M
        • Ahn JB
        • Deng YH
        • Kato T
        • Cho SH
        • Ba Y
        • Matsuoka H
        • Lee KW
        • Zhang T
        • Yamada Y
        • Sakamoto J
        • Park YS
        • Kim TW.
        Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
        Lancet Oncol. 2018; 19: 660-671
        • Hubbard JM
        • Grothey A.
        Napabucasin: an update on the first-in-class cancer stemness inhibitor.
        Drugs. 2017; 77: 1091-1103